Free tool
FAERS Monitor: Zenbexus
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 221075 or its brand name (Zenbexus, Iberdomide Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
149
Serious
143
96% of reports
Hospitalization
90
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia22
- neutropenia19
- pneumonia13
- thrombocytopenia12
- covid-1911
- plasma cell myeloma10
- infection8
- fatigue7
- mixed liver injury7
- rash7
- anaemia6
- phlebitis6
- sepsis6
- bone marrow failure5
- covid-19 pneumonia5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 20 |
| 2023 | 64 |
| 2024 | 11 |
| 2025 | 21 |
| 2026 | 23 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,010 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| mixed liver injurySignal | 7 | 329.2 | 159.6 | 1,969 |
| phlebitisSignal | 6 | 165.6 | 75.6 | 823 |
| covid-19 pneumoniaSignal | 5 | 59.8 | 25.3 | 233 |
| febrile neutropeniaSignal | 22 | 46.8 | 31.8 | 944 |
| plasma cell myelomaSignal | 10 | 36.2 | 19.9 | 308 |
| bone marrow failureSignal | 5 | 34.7 | 14.7 | 132 |
| neutropeniaSignal | 19 | 19.7 | 13.0 | 321 |
| thrombocytopeniaSignal | 12 | 15.1 | 8.8 | 146 |
| covid-19Signal | 11 | 8.9 | 5.0 | 70 |
| infectionSignal | 8 | 7.8 | 4.0 | 41 |
| sepsisSignal | 6 | 7.6 | 3.5 | 28 |
| pneumoniaSignal | 13 | 5.7 | 3.4 | 46 |
| anaemiaSignal | 6 | 4.4 | 2.0 | 13 |
| rash | 7 | 2.3 | 1.1 | 4 |
| fatigue | 7 | 1.3 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.